Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment of Celotres. The study, presented by Brian Berman, MD, PhD, during the South Beach Clinical Dermatology and Aesthetics Symposium, was intended to evaluate the safety and clinical feasibility of Celotres, an injectable hydrogel scaffold, in the prevention, reduction, or improvement of keloid scars after surgical excision. The passive device comprised of porcine gelatin stabilized with dextran was  injected into the dermal/subdermal space of the surgical wound post-excision of the existing keloid and prior to final suturing.  
Among 26 earlobe keloids (19 subjects) treated with Celotres, the 12-month keloid recurrence rate was 19.2% (5/26 keloids) vs. a scientific literature rate of 51.2%.  More information is available at  Halscion.net.